AU Patent

AU2007253254B2 — Cladribine regimen for treating multiple sclerosis

Assigned to Merck Serono SA · Expires 2013-01-17 · 13y expired

What this patent protects

The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.

USPTO Abstract

The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.

Drugs covered by this patent

Patent Metadata

Patent number
AU2007253254B2
Jurisdiction
AU
Classification
—
Expires
2013-01-17
Drug substance claim
No
Drug product claim
No
Assignee
Merck Serono SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.